Agreements reached under this partnership
Option and license agreement- 1
Grant of an option for an exclusive license covering the evaluation, development, manufacture and sale of veterinary pharmaceuticals containing the licensed compound, among other activities
- 2
Receipt of the option exercise fee
- 3
Acquisition of the right to receive development milestone payments based on development progress
- 4
Potential receipt of sales royalties and sales milestones based on product sales
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The upfront payment will be received and recorded as business revenue for the second quarter of the fiscal year ending December 2026. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the current fiscal year announced on 13 February 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Velovia Pharma, LLC |
| Alliance partner's location | United States |
| Type of alliance | Option and license agreement |
| Details of the alliance | Grant of an option for an exclusive license covering the evaluation, development, manufacture and sale of veterinary pharmaceuticals containing the licensed compound, among other activities, Receipt of the option exercise fee, Acquisition of the right to receive development milestone payments based on development progress, Potential receipt of sales royalties and sales milestones based on product sales |
| Contract Date | 3 April 2024 |
| Impact on Business Performance | The upfront payment will be received and recorded as business revenue for the second quarter of the fiscal year ending December 2026. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the current fiscal year announced on 13 February 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Velovia Pharma, LLC exercised its option to obtain a license to develop a veterinary pharmaceutical based on the compound.